, Ophthalmology Department, vol.5

, Rue de Charenton, Paris Cedex 12, France. 3 Ophthalmology Department, Hôpital Général, 3, Rue du Faubourg Raines, 21033 Dijon, France. 4 Ophthalmology Department 2, Centre Hospitalier National des Quinze-Vingts, 28, Rue de Charenton, Paris Cedex 12, France. 5 Ophthalmology Department, Hôpital d'Instruction des Armées du Val de Grâce, vol.28

O. Department and . Huriez, , vol.1, p.69006

F. ;. Lyon, S. Resnikoff, D. Pascolini, D. Etya'ale, I. Kocur et al., Global data on visual impairment in the year 2002, Bull World Health Organ, vol.1, pp.844-851, 2004.

D. S. Friedman, M. R. Wilson, J. M. Liebmann, R. D. Fechtner, and R. N. Weinreb, An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma, Am J Ophthalmol, vol.138, issue.3, pp.19-31, 2004.

M. A. Kass, M. Gordon, R. E. Morley, . Jr, D. W. Meltzer et al., Compliance with topical timolol treatment, Am J Ophthalmol, vol.103, pp.188-193, 1987.

M. C. Leske, A. Heijl, L. Hyman, B. Bengtsson, L. Dong et al., Predictors of long-term progression in the early manifest glaucoma trial, Ophthalmology, vol.114, pp.1965-1972, 2007.

, The AGIS Investigators: The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration, Am J Ophthalmol, vol.130, pp.429-440, 2000.

A. Heijl, M. C. Leske, B. Bengtsson, L. Hyman, B. Bengtsson et al., Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial, Arch Ophthalmol, vol.120, pp.1268-1279, 2002.

M. C. Leske, A. Heijl, M. Hussein, B. Bengtsson, L. Hyman et al., Early Manifest Glaucoma Trial Group: Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial, Arch Ophthalmol, vol.121, pp.48-56, 2003.

P. R. Lichter, D. C. Musch, B. W. Gillespie, K. E. Guire, N. K. Janz et al., CIGTS Study Group: Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery, Ophthalmology, vol.108, pp.1943-1953, 2001.

A. Alm and J. Stjernschantz, Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol, Scandinavian Latanoprost Study Group. Ophthalmology, vol.102, pp.1743-1752, 1995.

C. B. Camras, Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States, Ophthalmology, vol.103, pp.138-147, 1996.

P. Watson and J. Stjernschantz, A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension, Ophthalmology, vol.103, pp.126-137, 1996.

R. Varma, L. J. Hwang, J. W. Grunden, G. W. Bean, and M. B. Sultan, Assessing the efficacy of latanoprost vs timolol using an alternate efficacy parameter: the intervisit intraocular pressure range, Am J Ophthalmol, vol.148, pp.221-226, 2009.

. Denis, BMC Ophthalmology, vol.10, 2010.

K. Hedman and L. I. Larsson, The effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican open-angle glaucoma or ocular hypertensive patients, Surv Ophthalmol, vol.47, issue.1, pp.77-89, 2002.

, Collaborative Normal-Tension Glaucoma Study Group: Comparison of glaucomatous progression between untreated patients with normaltension glaucoma and patients with therapeutically reduced intraocular pressures, Am J Ophthalmol, vol.126, pp.487-497, 1998.

R. K. Parrish, P. Palmberg, and W. P. Sheu, XLT Study Group: A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study, Am J Ophthalmol, vol.135, pp.688-703, 2003.

N. Orzalesi, L. Rossetti, A. Bottoli, and P. Fogagnolo, Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension, Ophthalmology, vol.113, pp.239-246, 2006.

N. Yildirim, A. Sahin, and S. Gultekin, The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma, J Glaucoma, vol.17, pp.36-39, 2008.

A. Bayer, W. Weiler, U. Oeverhaus, F. E. Skrotzki, and W. C. Stewart, the XPLORE Observation Group: Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies, J Ocul Pharmacol Ther, vol.20, pp.470-478, 2004.

I. Goldberg, X. Y. Li, P. Selaru, and D. Paggiarino, A 5-year, randomized, open-label safety study of latanoprost and usual care in patients with open-angle glaucoma or ocular hypertension, Eur J Ophthalmol, vol.18, pp.408-416, 2008.

K. Hedman and A. Alm, A pooled-data analysis of three randomized, doublemasked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol, Eur J Ophthalmol, vol.10, pp.95-104, 2000.

A. Ang, M. A. Reddy, L. Shepstone, and D. C. Broadway, Long term effect of latanoprost on intraocular pressure in normal tension glaucoma, Br J Ophthalmol, vol.88, pp.630-634, 2004.

A. H. Rulo, E. L. Greve, H. C. Geijssen, and P. F. Hoyng, Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma, Ophthalmology, vol.103, pp.1276-1282, 1996.

B. Dawson-saunders and R. B. Trapp, Basic and Clinical Biostatistics, 1990.

, European Glaucoma Society Terminology and Guidelines for Glaucoma, 2008.

. Lumigan, , 2006.

. Travatan, , 2005.

. Xalatan, , 2003.

M. A. Kass, D. K. Heuer, E. J. Higginbotham, C. A. Johnson, J. L. Keltner et al., The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma, Arch Ophthalmol, vol.120, pp.701-713, 2002.

A. L. Coleman and J. Caprioli, The logic behind target intraocular pressure, Am J Ophthalmol, vol.147, pp.379-380, 2009.

C. M. Olthoff, J. S. Schouten, . Borne-van-de, . Bw, and C. A. Webers, Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review, Ophthalmology, vol.112, pp.953-961, 2005.

J. H. Gurwitz, R. J. Glynn, M. Monane, D. E. Everitt, D. Gilden et al., Treatment for glaucoma: adherence by the elderly, Am J Public Health, vol.83, pp.711-716, 1993.

A. L. Robin, G. D. Novack, D. W. Covert, R. S. Crockett, and T. S. Marcic, Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use, Am J Ophthalmol, vol.144, pp.533-540, 2007.

M. Krousel-wood, S. Thomas, P. Muntner, and D. Morisky, Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients, Curr Opin Cardiol, vol.19, pp.357-362, 2004.

A. R. Feinstein, On white-coat effects and the electronic monitoring of compliance, Arch Intern Med, vol.150, pp.1377-1378, 1990.

B. L. Nordstrom, D. S. Friedman, E. Mozaffari, H. A. Quigley, and A. M. Walker, Persistence and adherence with topical glaucoma therapy, Am J Ophthalmol, vol.140, pp.598-606, 2005.

G. Reardon, G. F. Schwartz, and E. Mozaffari, Patient persistency with pharmacotherapy in the management of glaucoma, Eur J Ophthalmol, vol.13, pp.44-52, 2003.

G. Reardon, G. F. Schwartz, and E. Mozaffari, Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study, Clin Ther, vol.25, pp.1172-1185, 2003.

G. F. Schwartz, G. Reardon, and E. Mozaffari, Persistency with latanoprost or timolol in primary open-angle glaucoma suspects, Am J Ophthalmol, vol.137, issue.1, pp.13-16, 2004.

T. J. Zimmerman, S. R. Hahn, L. Gelb, H. Tan, and E. E. Kim, The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: change in prescription patterns and patient persistence, J Ocul Pharmacol Ther, vol.25, pp.145-152, 2009.